The Semax stroke-rehabilitation trial programme — what the Russian post-stroke evidence actually shows

Semax has been studied across a range of indications in Russia since its 1994 regulatory approval, but the deepest clinical-evidence body is in ischaemic stroke rehabilitation. The reasons are partly mechanistic and partly historical. Mechanistically, Semax acts through pathways — BDNF/NGF induction, monoaminergic modulation, antioxidant defence — that are all directly relevant to the ischaemic injury cascade and the subsequent recovery process. Historically, the Russian neurological community pursued the post-stroke indication aggressively in the late 1990s and 2000s, producing a continuous stream of trial work that has not been matched in any other Semax indication.

The trial programme is not a single study but a collection of multicentre Russian trials, mostly run through state and academic hospital networks, accumulated across roughly fifteen years. Sample sizes range from a few dozen subjects to several hundred. The pooled body of work is the basis for Semax's continued clinical use in Russian post-stroke care and for its inclusion on the Russian List of Vital and Essential Drugs.

The standard endpoints across the programme are the NIH Stroke Scale (NIHSS) for neurological deficit, the Barthel Index for activities of daily living, and the Mini-Mental State Examination or Russian-language equivalent for cognitive function. Trials run on a 10–14 day cycle of intranasal Semax administration, typically initiated within the first few days after the index stroke event, with assessments at baseline, end-of-treatment, and at follow-up windows ranging from 30 to 90 days.

The intervention is adjunct to standard rehabilitation care rather than a replacement for it. The comparison arm receives the same physiotherapy, occupational-therapy, and pharmacological-care protocol as the intervention arm; the intervention arm adds intranasal Semax on top. The question the trials are designed to answer is therefore narrow and well-posed: does adding Semax to standard care produce measurably faster or more complete neurological recovery?

The consistent finding across the trial body is faster neurological recovery in the Semax arm. NIHSS improvement is typically reported as occurring more rapidly in the treated group, with statistical separation appearing within the first 7–10 days of treatment and persisting at the 30-day follow-up window. The magnitude of the effect varies across studies — published effect sizes range from modest to substantial — but the direction is consistent.

Barthel Index improvements track NIHSS improvements, with treated subjects regaining independence in activities of daily living more quickly. Cognitive measures show smaller but still positive effects, with the strongest signals in the speech-function and attention sub-domains. Quality-of-life and subjective-wellbeing measures, where collected, show concordant patterns.

The neurological-recovery effect is most reliably demonstrable in moderate-severity strokes — NIHSS scores in the 8–15 range. In very mild strokes, both arms recover quickly and the differential is hard to detect; in very severe strokes, the underlying tissue damage limits the recovery ceiling and the marginal effect of the intervention is small.

Several caveats are appropriate when assessing the strength of this evidence body from a Western standpoint.

The trials are predominantly open-label or single-blind rather than double-blind placebo-controlled. Russian clinical-trial methodology of the 1990s and 2000s did not always reach the standards now expected in Western regulatory submissions, and some of the published reports omit details that would be required in a Cochrane-style systematic review.

The trials are concentrated in a small number of Russian centres with shared training and methodology. Cross-centre methodological independence is more limited than would be expected from a comparable Western multicentre programme.

Publication bias is plausible. The available trials are uniformly positive; null trials may exist in unpublished form and would change the pooled picture.

The trial body has not been subjected to a full independent Western meta-analysis. The available systematic reviews are largely Russian and may share methodological assumptions with the underlying trials.

The Russian post-stroke Semax trial body is the strongest single-peptide clinical evidence base in the cognitive-peptide field, and the post-stroke indication is correspondingly the strongest claim that can be made for the compound. It is, however, not strong enough on its own to support Western regulatory authorisation, and the gap between 'consistent positive signal in Russian trials' and 'meets MHRA or FDA standard for licensing' is meaningful.

For research purposes the trial body provides a credible mechanistic and clinical context for investigating Semax in ischaemic-injury and post-stroke recovery models. For clinical purposes — outside Russia — Semax remains a research chemical, not an approved post-stroke therapy, and the trial body is properly understood as supporting research interest rather than licensed clinical use.